Bifogade filer
PDF
Lund, Sweden, October 3, 2024. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), will publish its interim report for January-September 2024 on October 17, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be made available on the company website at the following link: Financial reports (https://www.hansabiopharma.com/investors/financial-reports/).
To participate in the telephone conference, please use the dial-in details provided below:
Participant Toll Free Dial-in: 1-877-270-2148
International Dial-in: 1-412-902-6510
The webcast will be available on https://event.choruscall.com/mediaframe/webcast.html?webcastid=ld2DsRXz
--- ENDS ---
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com